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Abstract
Background: Histological examinations of MMTV-Wnt1 tumors reveal drastic differences in the tumor vasculature when
compared to MMTV-Her2 tumors. However, these differences have not been formally described, nor have any angiogenic
factors been implicated to be involved in the Wnt1 tumors.
Methodology/Principal Findings: Here, we show that MMTV-Wnt1 tumors were more vascularized than MMTV-Her2
tumors, and this correlated with significantly higher expression of a CXC chemokine, stromal cell-derived factor-1 (SDF1/
CXCL12) but not with VEGFA. Isolation of various cell types from Wnt1 tumors revealed that SDF1 was produced by both
tumor myoepithelial cells and stromal cells, whereas Her2 tumors lacked myoepithelial cells and contained significantly less
stroma. The growth of Wnt1 tumors, but not Her2 tumors, was inhibited by a neutralizing antibody to SDF1, but not by
neutralization of VEGFA. Anti-SDF1 treatment decreased the proportion of infiltrating Gr1
+ myeloid cells in the Wnt1 tumors,
which correlated with a decrease in the percentage of endothelial cells. The involvement of Gr1
+ cells was evident from the
retardation of Wnt1 tumor growth following in vivo depletion of these cells with an anti-Gr1-specific antibody. This degree
of inhibition on Wnt1 tumor growth was comparable, but not additive, to the effect observed with anti-SDF1, indicative of
overlapping mechanisms of inhibition. In contrast, Her2 tumors were not affected by the depletion of Gr1
+ cells.
Conclusions/Significance: We demonstrated that SDF1 is important for Wnt1, but not for HER2, in inducing murine
mammary tumor and the role of SDF1 in tumorigenesis involves Gr1
+ myeloid cells to facilitate growth and/or angiogenesis.
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Introduction
Mutations in components of canonical Wnt signaling pathway
are involved in a variety of human cancers (reviews [1,2]). This
transforming potential is borne out in mouse models where
overexpression of Wnt1 or a stable form of the intracellular
signaling effector, b-catenin (DN89b-catenin or DNbcat), under
the control of the mouse mammary tumor virus (MMTV) long-
terminal repeat induces mammary adenocarcinoma [3–5].
Although the mechanism by which Wnt signaling effectors induce
mammary tumorigenesis remains unclear, these tumors harbor
distinguishing histological features when compared to other
mammary tumors induced by overexpression of Her2 or Polyoma
middle T antigen (PyMT) driven by the same MMTV promoter.
First, Wnt signaling-induced tumors are composed of both ductal
luminal cells and contractile myoepithelial cells, whereas Her2 and
PyMT tumors contain only luminal cells. Second, a significant
portion of the Wnt1 tumors is comprised of stroma, but stroma is
minimal in the Her2 tumors [6]. Finally, Wnt1 tumors are
frequently filled with blood and lymphocytic infiltrates [3,6],
whereas Her2 tumors are generally pale and devoid of obvious
blood-filled regions. These observations suggest that tumor-
initiating cells, stromal-epithelial interactions, and tumor vascu-
larization should be obviously different between Wnt1 and Her2
tumors.
Tumor angiogenesis is a rate limiting step in tumor growth, and
neo-vascularization can be achieved by a number of ways. Newly
forming blood vessels are often sprouted from pre-existing vessels
involving the dissociation, migration, and division of differentiated
endothelial cells. Micro-vessels can also be synthesized de novo by
contributions of bone marrow-derived cells (BMDCs). Various
BMDCs such as endothelial progenitor cells, tumor-associated
macrophages, Tie2-expressing monocytes, and myeloid progenitor
cells, have been shown to participate in tumor angiogenesis and
facilitate tumor growth [7–13]. Recent studies have shown that
Wnt1 tumors recruit BMDCs to the tumor site, and these
progenitor cells can be incorporated into the stroma, possibly
contributing to tumor angiogenesis [14]. Some BMDCs express
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bone marrow to sites producing the chemokine ligand, SDF1
[15,16]. The importance of the SDF1-CXCR4 axis in angiogen-
esis is apparent from the lack of gastrointestinal blood vessels in
CXCR4
2/2 mice, and SDF1 has been shown to contribute to
angiogenesis in gastrointestinal tumor models [17].
There is compelling evidence linking Wnt signaling to
vascularization. In particular, genetic defects in the Wnt receptor,
frizzled4, are associated with familial exudative vitreoretinopathy
(FEVR), characterized by incomplete retinal neovascularization.
Frizzled4
2/2 mice exhibit leaky vasculature in the retina and
cerebellum, and genetic disruption of Wnt2 and frizzled5 results in
placental vascularization defects (review [18]). Despite these
findings, the mechanism by which Wnt signaling regulates
vasculature and which angiogenic factors are linked to Wnt
signaling remains unclear. In colon cancer cell lines, Wnt signaling
can increase transcription of VEGFA, and elevated levels of
VEGFA have been detected in intestinal polyps of APC
min/+ mice
and in human colon cancers relative to matched normal colon
tissues [19].
Here, we examined vasculature and potential angiogenic factors
in Wnt signaling-induced mammary tumors, and found that SDF1
to be a more important factor than VEGF in facilitating tumor
growth. We propose a model in which Wnt1 tumors utilize
Gr1
+CD11b
+ cells for angiogenesis and growth by producing
SDF1.
Results
Wnt1 Tumors Are More Vascularized Than Her2 Tumors,
and This Correlates with Higher Levels of SDF1, but Not
with VEGFA
We examined the micro-vessel density in Wnt1 and Her2
tumors by immunohistochemical staining of tumor sections with
anti-CD31 antibody, a platelet endothelial cell adhesion molecule
(PECAM1) marker. Average CD31
+ vessel counts were 62.3 per
0.45 mm
2 section for Wnt1 tumors as compared to 25.3 for Her2
tumors (Fig. 1A). Quantitation of MECA32
+ cells (a pan-
endothelial cell marker) in the tumors by fluorescent activating
cell sorting (FACS) showed that Wnt1 tumors contained 10.8%
MECA32
+ cells, which was approximately 3-fold higher than the
percentage of MECA32
+ in the Her2 tumors (Fig. 1B). Consistent
with the FACS data, Wnt1 tumor sections stained with anti-
MECA32 antibody contained a higher proportion of MECA32
+
cells than in Her2 tumor sections (Fig. S1A).
A number of factors are known to contribute to tumor
angiogenesis, including VEGF, basic FGF (bFGF), TNFa, and
SDF1. Upon examining these in a panel of primary MMTV
tumors and those passaged in mice, we found that the Wnt1
tumors expressed SDF1a and b transcripts at levels at least 7-fold
higher than that detected in Her2 or PyMT tumors (Fig. 1C, Fig.
S1B; p=0.003). Higher amounts of SDF1a proteins were also
immunoprecipitated from Wnt1 tumor lysates than from Her2
tumor lysates, and higher amounts of secreted SDF1a proteins
were detected in the media of cultured Wnt1 tumor cells vs. Her2
tumor cells (Fig. 1D, E). In contrast, VEGFA transcript levels were
generally higher in the Her2 and PyMT tumors relative to Wnt1
tumors (Fig. 1C). Expression of bFGF transcript was comparable
between Wnt1 and Her2 tumors, and no significant distinction in
its expression was noted across the various types of tumors. Slightly
higher levels of TNFa transcript were detected in Wnt1 tumors
relative to Her2 tumors, although this difference was smaller than
that observed for SDF1a. Thus, we focused on determining the
role of SDF1 in Wnt-induced tumorigenesis.
SDF1 Is Produced by Myoepithelial Cells and Stromal
Fibroblasts in Wnt1 Tumors
Although SDF1 is typically considered to be secreted by stromal
cells, tumor epithelial cells remain a possible source (review [20]).
To determine what types of cells in the Wnt1 tumors express
SDF1, we injected dissociated Wnt1 tumor cells into the
mammary fat pads of immune-deficient Rag2
2/2mice constitu-
tively expressing an enhanced green fluorescent protein under
control of the chicken b-actin promoter (EGFPtg/Rag2
2/2). The
resulting tumor cells can be sorted based on GFP positivity,
allowing for the separation of tumor epithelial cells from host
stromal cells. Analysis of these isolated cell populations revealed
that SDF1a transcript levels were consistently higher in the Wnt1
epithelial cells (GFP
2) vs. Her2 epithelial cells, whereas SDF1a
transcript levels in the Wnt1 stroma cells (GFP
+) were not
significantly higher compared to the Her2 stromal cells (Fig. 2A).
A major distinction between Wnt1 and Her2 tumor epithelial
cells is the presence of myoepithelial cells in Wnt1 tumors, which
could account for the expression of SDF1. This would be
consistent with the reported expression of SDF1 in human
mammary myoepithelial cells [21] and with our observed
correlation between SDF1a expression and the presence of
myoepithelial cell marker transcripts (Fig. S2A). Therefore, we
sought to separate the tumor myoepithelial and luminal cell
populations to analyze them for expression of SDF1. Although
isolation of myoepithelial and luminal cells from human mammary
tissues has been described, the cell surface markers (CD10/
CALLA for myoepithelial cells and BerEP4 for luminal cells;
[21,22]) used in those isolations are not suitable for mouse cells.
Thus, mouse mammary myoepithelial and luminal cells have not
been isolated. We found that P-cadherin is a suitable myoepithelial
marker for isolation of mouse myoepithelial cells [23]. P-cadherin
staining overlapped with that of CK5, a known myoepithelial cell
marker, but not with CK18, a luminal cell marker (Fig. 2B). Also,
P-cadherin
+ cells were not found in Her2 tumors, and all of the
Her2 tumor cells were CK18
+.
To isolate myoepithelial cells, tumors were grown in EGFPtg/
Rag2
2/2 mice. Tumor cells were dissociated, incubated with anti-
P-cadherin, -EpCAM, and -CD45 antibodies, and sorted by
FACS. Hematopoietic cells were first excluded by gating on
CD45
2 populations. Then, the GFP
+CD45
2 host cells were gated
and separated from the tumor epithelial cells. The remaining
GFP
2EpCAM
+ cells were further gated based on P-cadherin and
EpCAM signals (Fig. 2C).
Upon examining the sorted cells by immunocytochemistry, the
P-cadherin
+EpCAM
lo cell fraction was enriched for CK5
+ cells
and depleted for CK18
+ cells (Fig. S2B). In contrast, P-
cadherin
2EpCAM
hi cell fraction was enriched for CK18
+ cells
and depleted for CK5
+ cells. Consistent with immunocytochem-
ical results, high levels of myoepithelial cell marker transcripts
(CK5, P-cadherin, and a-SMA) were found in P-cadherin
+Ep-
CAM
lo cells and high levels of luminal cell transcripts (CK18 and
mucin-1) were found in P-cadherin
2EpCAM
hi cells (Fig. 2D, data
not shown).
Once myoepithelial and luminal cells were separated, we
determined that SDF1a transcript was found only in the
myoepithelial cells of Wnt1 tumors, but not in the luminal cells
(Fig. 2D). Her2 tumors only contained luminal cells (P-cadher-
in
2EpCAM
hi), which did not express SDF1a. We noted that
GFP
+CD45
2 cells also expressed SDF1a, and these cells appear to
be a fibroblast-enriched population based on their expression of
fibroblast markers, vimentin and FSP1 (Fig. 2D, Fig. S2B, data not
shown). We also detected much higher levels of secreted SDF1a
protein in the media of cultured myoepithelial cells and fibroblasts
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PLoS ONE | www.plosone.org 2 January 2010 | Volume 5 | Issue 1 | e8611Figure 1. Analysis of Wnt1 tumor vasculature and potential factors that contribute to tumor vasculature. A, immunohistochemical
stained Wnt1 and Her2 tumor sections with anti-CD31 antibody (brown) and hematoxylin (blue). The inserts are zoomed in regions of the tumor
sections, which were used to score for micro-vessel density. Average numbers of CD31
+ vessels per 0.45 mm
2 are shown for each tumor types, and
averages were derived from scoring three random sections per tumor, and n=3 tumors for Wnt1 and Her2. +/2 values represent standard deviations.
B, quantitation of MECA32
+ cells in tumors by FACS analysis. Average percentage of MECA32
+ cells was derived from analysis of five independent
Wnt1 (dark bar) and Her2 tumors (light bar), and error bars represent +/2 SEM. C, qRT-PCR analysis of indicated mRNA transcript levels in various
MMTV tumors and normal mammary glands. Primary Wnt1 tumors are as indicated, and all of the other tumors are from passaged tumors. All
reactions were performed in duplicates and relative mRNA level for each gene was calculated by normalizing to average transcript levels of normal
mammary glands. D, immunoblot analysis of SDF1 protein immunoprecipitated from lysates of Wnt1 and Her2 tumors, and aliquots of input tumor
lysates for immunoprecipitation were blotted for b-actin. E, ELISA analysis of secreted SDF1a protein in media taken from cultured normal mammary
gland cells, Wnt1 tumor cells, and Her2 tumor cells. Media were collected from five individually plated tumor or normal mammary cells, and
* indicates that lower amount of secreted SDF1a in the Her2 cell media is statistically significant.
doi:10.1371/journal.pone.0008611.g001
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PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8611Figure 2. Expression of SDF1 in various cell types from Wnt1 tumors. Dissociated Wnt1 or Her2 tumor cells were injected into the mammary
fat pads of EGFPtg/Rag2
2/2 mice, and isolated GFP
2 (tumor cells; light bars) and GFP
+ (stromal cells; black bars) cells were subjected to qRT-PCR
analysis of SDF1a expression (A). SDF1a transcript levels were normalized to one of the Her2 GFP
+ tumor cell sample (lane 1). B, immunofluorescent
staining of Wnt1 and Her2 tumor sections with anti-P-cadherin (green), -CK5 (red; left panel), -CK18 antibodies (red; right panel), and DAPI in blue.
Merged pictures of P-cadherin staining with CK5 (yellow; left panel) and with CK18 (right panel) are shown. C, FACS gating scheme for isolation of
myoepithelial and luminal cells from Wnt1 and Her2 tumors grown in EGFPtg/Rag2
2/2 mice. EpCAM
+GFP
2 cells were further analyzed based on
EpCAM and P-cadherin staining. D, qRT-PCR analysis of the indicated mRNA transcripts in the sorted Wnt1 and Her2 tumor cell populations. Relative
mRNA transcript levels were normalized to that of the unsorted Wnt1 cell population, and error bars represent standard deviations derived from
three independent tumor sorts.
doi:10.1371/journal.pone.0008611.g002
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SDF1 in the Wnt1 tumors relative to Her2 tumors are due to the
presence of myoepithelial cells and higher stromal fibroblasts
content.
SDF1 Expression Is Not Induced by Wnt Signaling
The correlation between the expression of SDF1a and axin2, a
known Wnt signaling responsive gene, implies that SDF1 is also a
Wnt signaling responsive gene (Fig. 2D). To test this, we cultured
primary mammary cells from female C57BL6 mice in conditioned
media from Wnt3A-producing L-cells or in L-cell control media.
With increasing amount of Wnt3A conditioned media, expression
of axin2 transcript increased to a 5-fold maximum relative to
control. Also, the increase in axin2 transcript levels was completely
inhibited by FzD8-CRD, a soluble Wnt ligand inhibitor (Fig. 3A;
[24]). In contrast, SDF1a and CXCR4 transcript levels remained
unchanged in cells cultured in Wnt3A conditioned media relative
to L-cell media, and were not decreased upon addition of FzD8-
CRD. To test whether suppression of Wnt signaling in vivo has an
effect on SDF1a mRNA transcript, Wnt1 tumor-bearing mice
were injected with FzD8-CRD. Axin2 transcript in tumors taken
from FzD8-CRD treated mice decreased by ,3-fold as early as 6
hour post-treatment and remained depressed throughout the time
course relative to tumors from PBS treated mice. However, no
concomitant decrease in SDF1a transcript levels was observed
following FzD8-CRD treatment (Fig. 3B).
Our results indicate that the elevated levels of SDF1 in Wnt1
tumors are not due to a direct activation of this gene by Wnt
signaling. Since levels of SDF1a transcript in normal mammary
glands and secreted SDF1a in the media of cultured normal
mammary cells were not significantly different from that of Wnt1
tumors (Fig. 1C, E), SDF1 expression in the tumors could simply
be attributed to the presence of myoepithelial cells and fibroblasts
that normally express SDF1. To test this, myoepithelial cells and
fibroblasts were isolated from normal mammary glands and
Wnt1 tumors. The level of SDF1a transcript was not different
between normal myoepithelial cells and fibroblasts and their
corresponding cell fractions from Wnt1 tumors (Fig. 3C). In
contrast, axin2 transcript levels were 2.4 to 2.6-fold higher in
myoepithelial cells and fibroblasts isolated from Wnt1 tumors
relative to their corresponding cells from normal mammary
glands.
Inhibition of Wnt Signaling-Induced Tumor Growth by
Neutralization of SDF1
Since MMTV-Wnt1 tumors expressed significantly higher
levels of SDF1 than the other MMTV tumors (Fig. 1C–E), we
asked whether SDF1 was functionally relevant to tumorigenesis.
To test this, dissociated tumor cells were injected into nude mice,
and tumor-bearing mice were treated with functional perturbing
anti-SDF1 antibody or with control anti-HSV Glycoprotein D
(GD) antibody three times per week. Following treatments, anti-
SDF1 antibody significantly inhibited Wnt1 tumor growth, and
the average tumor size of control anti-GD treated group (n=10)
was 1,266 mm
3 where as anti-SDF1 treated group was 674 mm
3
(p=0.029; Fig. 4A). We also repeated this experiment with a
different MMTV-Wnt1 tumorline that harborsa spontaneous H-
ras mutation. Although this tumor grew much faster than the
previous Wnt1 tumor without H-ras mutation, a similar
inhibition of tumor growth with anti-SDF1 antibody was seen
(1,196 mm
3 for anti-GD group vs. 716 mm
3 for anti-SDF1
group; p,0.001). Since MMTV-DNbcat tumors also expressed
high levels of SDF1, we treated DNbcat tumor-bearing mice with
anti-SDF1 antibody and again saw a significant inhibition in
average tumor growth (anti-GD group: 1,043 mm
3 vs. anti-SDF1
group: 644 mm3; p=0.001). Finally, we tested the Her2 tumors,
which express very low levels of SDF1 and found that anti-SDF1
antibody did not inhibit their growth (anti-GD group: 2,170 mm
3
vs. anti-SDF1 group: 2,300 mm
3;p = 0 . 5 6 ) .T h e s er e s u l t s
demonstrate that SDF1, which can impact tumor angiogenesis,
significantly contributes to the growth of Wnt1 and DNbcat
tumors. Nevertheless, VEGF, previously reported to be a Wnt
signaling responsive gene, might also play a significant role in
angiogenesis and growth of the Wnt1 tumors. To test this, Wnt1
tumor-bearing mice were treated with anti-VEGF antibody
(blocks both VEGFA and VEGFB [25]) or with anti-Ragweed
control antibody three times per week. After the treatment, the
average tumor size for the anti-VEGF treated group was slightly
smaller than the anti-Ragweed treated group (1,354 mm
3 vs.
1,910 mm
3), but this difference was not statistically significant
(Fig. 4B; p=0.38).
Anti-SDF1 Antibody Treatment Reduces Gr1
+CD11b
+
Cells and Endothelial Cells in the Wnt1 Tumors
The impact of anti-SDF1 treatment on Wnt1 tumor growth
prompted us to examine the mechanism by which SDF1
contributes to Wnt1 tumor growth. It is known that SDF1 can
recruit BMDCs to facilitate tumor angiogenesis. Therefore, we
tested whether anti-SDF1 treatment can affect the amount of
BMDCs in the Wnt1 tumors. Among the various BMDCs,
including endothelial progenitor cells (CD34
+VEGFR2
+ and
CD31
+Sca1
+), macrophages (F4/80
+), and myeloid progenitor
cells (Gr1
+CD11b
+), the Gr1
+CD11b
+ cells underwent the most
consistent change following anti-SDF1 treatment (Fig. 5A, Fig.
S3A–C). At day 4 following anti-SDF1 treatments, the median
percentage of Gr1
+CD11b
+ cells in the anti-SDF1 treated tumors
was 4.86 and 8.47 for the anti-GD control treated tumors
(p=0.001). Consistent with the proposal that Gr1
+CD11b
+ cells
contribute to tumor angiogenesis, the percentage of endothelial
cells (MECA32
+) was also decreased following anti-SDF1
treatment (anti-SDF1 group: 4.95 vs. anti-GD group: 10.4;
p=0.009; Fig. 5B). Immunohistochemical staining of Wnt1 tumor
sections showed that regions lacking MECA32
+ cells were more
abundant and stained vessels were much slimmer in the anti-SDF1
treated tumors relative to control (Fig. 5C). Since similar levels of
SDF1 expression was found in normal mammary glands relative to
Wnt1 tumors, we also determined the effect of anti-SDF1
treatment on the amount of Gr1
+CD11b
+ cells residing in the
normal mammary glands. Normal mammary glands contained
,16.3% of Gr1
+CD11b
+ cells, and these cells were reduced to
10.7% following anti-SDF1 treatment (p=0.022; Fig. 5D),
suggesting that both Wnt1 tumors and normal mammary glands
utilize SDF1 to harbor these Gr1
+CD11b
+ cells.
Depletion of Total Gr1
+ Cells in Mice Inhibits Wnt1 Tumor
Growth
To test whether Gr1
+ cells are important for Wnt1 tumor
growth, the Gr1
+ cells can be depleted in vivo by administration of
anti-Gr1 antibody [26]. Wnt1 and Her2 tumor-bearing mice were
injected with anti-Gr1 (twice per week), anti-SDF1 (three times per
week), and a combination of both antibodies. Virtually all of the
Gr1
+ cells (mostly neutrophils) and the Gr1
+CD11b
+ double
positive cells (neutrophils and macrophages lineage) from bone
marrow and peripheral blood of tumor-bearing mice were
depleted upon treatment with anti-Gr1 antibody (Fig. 6A). Also,
the Gr1
+CD11b
+ cells in the tumors were significantly reduced
with anti-Gr1 treatment.
SDF1 Contributes to MMTV-Wnt1
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anti-Gr1 group was inhibited by 53% relative to control anti-GD
treated group (Fig. 6B; p=0.034), which was similar to the levels
of inhibition by anti-SDF1. However, anti-SDF1 treatment did not
add to the tumor inhibition observed in animals already depleted
of Gr1
+ cells. These data suggest that Gr1
+ cells are important for
Wnt1 tumor growth, and that SDF1 is responsible for the
involvement of these cells with Wnt1 tumors. Consistent with
Figure 3. Determination of whether SDF1 is a Wnt signaling responsive gene. A, qRT-PCR analysis of axin2, SDF1a, and CXCR4 transcript
levels in normal mammary epithelial cells cultured in Wnt3A conditioned media. Triplicate plated cells were cultured in control L-cell media:mammary
epithelial cell culture media (1:1 dilution), in Wnt3A conditioned media (1:2 or 1:1 dilution), and in Wnt3A conditioned media (1:1) + Fzd8-CRD (10 mg/
mL). Relative transcript levels were normalized to levels in L-cell media. Error bars represent standard deviations derived from triplicate plated cells. B,
qRT-PCR analysis of axin2 and SDF1a transcript levels in Wnt1 tumors taken from tumor-bearing mice that were treated with Fzd8-CRD at various
hours of post injection. Each time points contain samples from two independently FzD8-CRD treated mice numbered 1 and 2. Relative transcript
levels were normalized to the level in the 6 hour PBS-treated tumor sample. C, qRT-PCR analysis of axin2 and SDF1a transcript levels in the sorted cell
populations from Wnt1 tumors (dark bars) or from normal mammary glands (light bars). Cell populations were isolated from three independent Wnt1
tumors or from three independent pools of normal mammary glands (pools of glands from ,20 female C57BL6 mice). Error bars represent standard
deviations derived from the three independent tumors or pools of mammary gland sorts.
doi:10.1371/journal.pone.0008611.g003
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very low levels of SDF1, was not affected by anti-Gr1 depletion
(Fig. 6B).
Discussion
SDF1 Is an Important Factor for the Growth of Wnt
Signaling-Induced Mammary Tumors
It has been observed that MMTV-Wnt1 tumors frequently
contain blood-filled cysts and lymphocytic infiltrates [3,6].
However, tumor vasculature and factors that can contribute to
vascularization have not been clearly described for the Wnt1
tumors. Here, we report that Wnt1 tumors are more vascularized
than Her2 tumors, and SDF1 is a key factor in facilitating Wnt1
tumor growth and angiogenesis (Fig. 1 and 4).
We showed that Gr1
+CD11b
+ cells are important for Wnt1-
induced tumorigenesis, and their presence in the Wnt1 tumors
depends on SDF1 function. We detected a decrease in
Gr1
+CD11b
+ cells in the Wnt1 tumors following anti-SDF1
treatment (Fig. 5A), consistent with the reported ability of SDF1 to
attract these cells [15]. Our depletion of Gr1
+ cells in Wnt1 tumor-
bearing mice gave similar but no additional inhibition on Wnt1
tumor growth when combined with anti-SDF1, suggesting that
SDF1 and Gr1
+ cells have overlapping mechanisms in facilitating
Figure 4. MMTV tumor-bearing mice treated with anti-SDF1 and anti-VEGF antibodies. Dissociated MMTV tumor cells were injected into
nude mice, and tumor-bearing mice were injected with anti-SDF1 (circle) or control anti-GD (square) antibodies (A) and injected with anti-VEGF
(diamond) or control anti-Ragweed antibodies (triangle; B). Average tumor volume was calculated from n=10 treated mice for anti-SDF1 treatments
and n=5 for anti-VEGF treatment. Error bars represent +/2 SEM. * indicates average tumor volumes that are statistically different between anti-GD
and anti-SDF1 treatment groups (p,0.05).
doi:10.1371/journal.pone.0008611.g004
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PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8611Figure 5. Assessment of BMDC contributions and endothelial cell content in Wnt1 tumors and normal mammary glands following
anti-SDF1 treatment. FACS profiles and box plots of percentage of Gr1
+CD11b
+ cells (A) and MECA32
+ cells (B) in Wnt1 tumors (n=10) following
four days of anti-SDF1 treatment. C, immunofluorescent staining of Wnt1 tumor sections with anti-MECA32 antibody (red) and DAPI (blue) following
four days of anti-SDF1 treatment. Entire tumor section was assembled from ,100 images taken by fluorescent microscope with a 10X objective, and
inserts are zoom in depictions of that particular sections. D, FACS profiles and box plots of percentage of Gr1
+CD11b
+ cells in normal virgin mammary
glands following four days of anti-SDF1 treatment.
doi:10.1371/journal.pone.0008611.g005
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PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8611Figure 6. Tumor-bearing mice treated with anti-Gr1 and anti-SDF1 antibody. A, FACS profiles and histogram plots of percentage of
Gr1
+CD11b
+ cells in the bone marrow, peripheral blood, and tumors of Wnt1 and Her2 tumor-bearing mice treated with anti-GD (dark bars), anti-Gr1
(light bars), or anti-Gr1 and -SDF1(white bars) antibody. Error bars represent standard deviations derived from analysis of three independently treated
mice. B, average tumor volumes of Wnt1 (left panel) or Her2 (right panel) tumor-bearing mice treated with controls, PBS (black) and anti-GD (blue),
and with anti-SDF1 (red), -Gr1 (green) and both -SDF1 plus -Gr1 (orange) antibodies. Average tumor volume was determined from n=5 mice per
treatment group, and error bars represent +/2 SEM. * indicates average tumor volumes that are statistically different between anti-GD and anti-Gr1
treatment groups (p,0.05).
doi:10.1371/journal.pone.0008611.g006
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upon Gr1
+CD11b
+ cells for their growth, Wnt1 tumors are more
resistant to anti-VEGF treatment than anti-SDF1 treatment, a
property that was shown to be attributed to these Gr1
+CD11b
+
cells (Fig. 4B, [27]).
Gr1
+CD11b
+cells were first described as myeloid immune
suppressor cells that can inhibit maturation of antigen-presenting
dendritic cells, presumably allowing tumors to escape immune
surveillance [28–30]. However, we can exclude this mechanism as
our allograft tumors were grown in immune-deficient mice. More
recent findings support an alternative role for these cells in
contributing to tumor angiogenesis. Gr1
+CD11b
+ cells are
incorporated into CD31
+ blood vessels in tumors, where they
produce high levels of MMP9 which is required for newly
synthesized vessels [8,31]. Gr1
+CD11b
+ cells also express Bv8 to
enhance mobilization and facilitate tumor angiogenesis [32].
Thus, Gr1
+CD11b
+ cells might contribute to the vasculature in
Wnt1 tumors, and we showed that a reduction in these cells
correlated with a decrease in endothelial cells in the Wnt1 tumors
following anti-SDF1 treatment (Fig. 5). We also found that
Gr1
+CD11b
+ cells were significantly elevated in the peripheral
blood of tumor-bearing mice following anti-SDF1 treatment (Fig.
S3D). We believe that inhibiting SDF1 function prevents retention
of Gr1
+CD11b
+ cells in tissues (including tumors) that normally
express high levels of SDF1. Thus, anti-SDF1 treatment releases
Gr1
+CD11b
+ cells into blood circulation, precluding these cells
from participating in tumor vasculogenesis and tumorigenesis.
This interpretation agrees with the finding that CXCR4
antagonist, AMD3100, treatment induces rapid mobilization of
murine and human hematopoietic stem/progenitor cells [33].
It is also possible that SDF1 directly stimulates Wnt1 tumor
cells, as SDF1 has been shown to increase proliferation of human
breast cancer cell lines in in vitro cultures [21,34]. Although we did
observe a slight decrease in Ki67
+ cells in Wnt1 tumors following
anti-SDF1 treatment (data not shown), this could have been an
indirect effect resulting from a reduction in Gr1
+CD11b
+ cells
and/or angiogenesis. Indeed the effect of anti-SDF appeared to be
mediated by Gr1
+ cells because no further inhibition by anti-SDF1
was observed following their depletion. Moreover, in vitro
culturing of Wnt1 tumor cells in media containing purified
SDF1 or anti-SDF1 antibody did not show significant differences
in total cell viability (Fig. S4).
Wnt1 Tumors Use Factors Produced by Normal Mammary
Developmental Process for Their Growth
Elevated SDF1 expression has been described in a number of
tumorigenic conditions relative to normal settings. First, higher
SDF1 expression is found in tumor enhancing cancer-associated
fibroblast relative to patient matched non-cancerous mammary
fibroblasts [7]. Second, SDF1 expression is induced under hypoxic
conditions in a glioblastoma tumor model system through HIF1a,
suggesting that SDF1 expression is increased in rapidly growing
tumors deprived of oxygen supply [35]. Finally, higher levels of
SDF1 expression are found in myoepithelial cells and myofibro-
blasts of human ductal carcinoma in situ and invasive breast
cancers relative to the same cell fractions in normal mammary
glands [21]. Although we found high levels of SDF1 in Wnt
signaling-induced tumors, the expression was comparable to that
of normal mouse mammary glands, which is consistent with
previous findings [14]. Further fractionation revealed that the
levels of SDF1 expression in the myoepithelial cells and fibroblasts
isolated from normal mammary glands are comparable to the
levels found in the counterparts isolated from Wnt1 tumors
(Fig. 3C). Thus, high levels of SDF1 expression in the Wnt1
tumors are due to the presence of myoepithelial cells and/or
stromal fibroblasts, and unlikely associated with elevated Wnt
signaling.
It is also likely that the role of SDF1 in Wnt1-induced
tumorigenesis is similar to that in normal mammary gland
development. We did detect a decrease in Gr1
+CD11b
+ cells in
both the Wnt1 tumors and in normal mammary glands following
anti-SDF1 treatment (Fig. 5A, D). Moreover, recruitment of other
BMDCs such as macrophages and eosinophiles to the mammary
glands is a critical part of normal developmental process, as these
cells typically reside at the leading edge of developing mammary
terminal end buds [36]. The absence of these BDMCs results in
retardation of mammary ductal branching. Thus, Wnt tumors
may not depend on production of de novo factors for their growth;
but rather co-opt the existing resources available to them.
In conclusion, we demonstrate that SDF1 is a key factor in Wnt
signaling-induced mammary gland tumorigenesis. The source of
SDF1 is from myoepithelial cells and stromal fibroblasts of Wnt
signaling-induced tumors, and SDF1 supports tumorigenesis by
involving Gr1
+CD11b
+ cells. We propose that anti-SDF1 may be
an effective therapeutic strategy for targeting mammary tumors
with abundant amounts of myoepithelial cells and/or stromal cells
expressing SDF1.
Materials and Methods
Mice and Allograft Tumors
To generate immune-deficient mice constitutively expressing
GFP (EGFPtg/Rag2
2/2), EGFP transgenic mice (C57BL/6-Tg
(ACTB-EGFP) 1Osb/J, Jackson Laboratory) were crossed with
mice with a genetic disruption of Rag2 gene (B6.SJL (129S6)-
Ptprc
a/BoyCrTac-Rag2
tm1Fwa, Taconic). Athymic NCR-nude mice
(Taconic) were used for MMTV tumor transplants and antibody
treatments. Wnt1 tumors used for transplantations were from
MMTV-Wnt1 transgenic mice that were passaged in mammary
fat pads of C57/BL6 mice [24]. Her2 tumors were from
MMTV.f.huHER2 mice and passaged in FBV/N mice as
described in [37]. DNbcat tumors were obtained from Dr. Cowin
(NYU), and tumors were passaged in nude mice. All experimental
protocols using mice were approved by the Institutional Animal
Care and Use Committee at Genentech Inc.
Immunohistochemistry and Scoring of Micro-Vessel
Density
Tumors were fixed in 10% formalin, embedded in paraffin for
histological sectioning, and sections were subjected to antigen
retrieval following the protocol described from the Rosen
laboratory (http://www.bcm.edu/rosenlab/protocols/generalIF.
pdf). Tumor sections were blocked by MOM (Vector Laborato-
ries), and incubated with primary antibodies, anti-CD31 (Abcam),
-MECA32 (BD Biosciences), -P-cadherin (R&D Systems, goat
polyclonal), -cytokeratin 5 (CK5; Abcam) and -cytokeratin 18
(CK18; Abcam, mouse monoclonal). For immunohistochemical
staining of sections, HRP-conjugated secondary antibody was used
followed by hematoxylin counterstaining. Scoring of micro-vessel
density was done by using a modified method described in [38].
Tumor sections were scanned at a low magnification (40x) to
identify areas with the highest density of CD31
+ blood vessels.
Three random areas with the highest vessel density were counted
at a higher magnification (200x; ,0.45 mm
3 section area), and
only structures with clear identifiable lumen were scored.
For immunofluorescent staining, Alexa488- or Alexa555-
conjugated secondary antibody was used followed by mounting
with Prolong Gold (Invitrogen) containing DAPI dye. Fluorescent
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images were processed with Axiovision and Adobe Photoshop
software.
Quantitative Real-Time PCR (qRT-PCR)
RNeasy miniprep kit (Qiagen) was used to isolate total RNA
from mammary tissues, tumors, and cells. 50 ng of RNA was mixed
in a 25 uL qRT-PCR master mix (Applied Biosystems Inc; ABI),
and reactions were carried out in a 7500 Real-time PCR system.
Relative transcript level for each gene was determined by using
2
2DDCt method and normalized to housekeeping RPL19 transcript
level. Taqman
TM primers used, RPL19: 59- GCGCATCCTCAT
GGAGCACA, 39- GGTCAGCCAGGAGCTTCTTG, probe -
CACAAGCTGAAGGCAGACAAGGCCC; Mouse Axin2: 59-G -
TGAGCTGGTTG TCACCTACTT, 39- AAGCTTTGAG-
CCTTCAGCAT, probe - TTCTGTGGAGAA GAAATTCCA-
TACAGGAGG; Mouse SDF1a:5 9-CATCCATCCATC-
CATCCA, 39- TTCAGGGTCATGGAGACAGT, probe -TC-
ATCGCCATGTGTCCGCAAG. All other primers and probes
were purchased from ABI.
Immunoprecipitation of SDF1 Protein from MMTV
Tumors
Tumor tissues were homogenized in lysis buffer (1 g of tissue per
10 mL of lysis buffer; Invitrogen) using Qiagen tissue homogeni-
zation system. Total protein concentration was determined by
BCA assay (Pierce), and 50 mg of protein lysate was used in the
immunoprecipitation with 100 mg of anti-SDF1 antibody (R&D
Systems). Immunoprecipitated protein was subjected to immuno-
blot analysis using anti-SDF1 antibody (Cell Signaling Technol-
ogy). Aliquots of input lysates for immunoprecipitation were also
subjected to immunoblot analysis by using anti-b-actin antibody as
a loading control.
ELISA Analysis of Cultured Wnt1 Tumor Cells, Her2 Tumor
Cells and Normal Mammary Gland Cells
Normal mammary glands (from 4–7 month-old C57BL/6
mice), Wnt1, and Her2 tumors were dissected, and cells were
disaggregated as described below. Cells were plated on 12 well
collagen I-coated plates (BD Bioscience) in 300 mL of mouse
mammary epithelial cell cultured media (Stemcell Technologies).
Once cells were confluent, media were collected and total protein
in media was determined by BCA assay. Media containing equal
amount of protein (200 mg) were used in ELISA assay by using
Mouse CXCL12/SDF1a Quantikine ELISA Kit (R&D Systems).
Colorimetric values were measured by microplate reader (Spec-
traMax 190) at 450 nm, and nonspecific readings at 540 nm were
subtracted from values measured at 450 nm.
Isolation of Myoepithelial and Luminal Cells
When Wnt1 or Her2 tumors grown in EGFPtg/Rag2
2/2 mice
reached ,500–1000 mm
3, tumors were dissected from mice,
minced into tiny pieces, and incubated in digestion media I (F12
media containing 4 mg/mL of collagenase I (sigma), 150 mg/mL
of hyaluronidase (sigma), 5% fetal bovin serum) for 90 minutes at
37uC with rocking. Red blood cells were lysed in hypotonic
solution. Semi-dissociated tumor cells were further digested to
single cells by incubation in digestion media II (F12 media
containing 4 mg/mL of collagenase I, 150 mg/mL of hyaluron-
idase, 5 mg/mL of dispase type II (Roche), 50 U/mL of DNase I
(Roche)) for 5 minutes at 37uC, then followed by incubation in
trypsin 0.25% +EDTA (Invitrogen) + 10 mM CaCl2 for 5 minutes
at 37uC. Trypsin was inactivated by washing cells twice with
RPMI + 10% FBS. Single cells were resuspended in washing
solution (PBS+1% BSA) and filtered through a 40 mM mesh.
Normal #4 and #5 mammary glands were dissected from twenty
4–7 month-old female C57BL/6 mice, chopped into small pieces,
and digested similarly as tumor cells. Dissociated cells were
incubated with P-cadherin antibody (R&D Systems) for 30
minutes at 4uC with shaking. Cells were washed and incubated
with secondary PE-conjugated anti-goat IgG, APC-conjugated
EpCAM (Biolegend), and APCcy7-conjugated CD45 (BD Biosci-
ence) antibodies for 30 minutes at 4uC. Following staining, cells
were resuspended in propidium iodide (5 mg/mL) and sorted by
FACSAria
TM cell sorter. FACS data were analyzed by FlowJo
software (Tree Star Inc.).
Wnt3A Conditioned Media Treatment of Primary Normal
Mammary Gland Cells
Dissociated primary mammary cells from C57BL/6 mice were
plated on collagen I-coated plates (BD Bioscience) in mouse
mammary epithelial cell cultured media. Following two days of
culture, cells were incubated with Wnt3A conditioned media (from
Wnt3A producing L-cells) or with control media (from L-cells) for
another 24 hours at which cells were collected and total RNA was
extracted. Conditioned media was diluted at various ratios with
mammary cell culture media as indicated.
In Vitro Treatment of Wnt1 Tumor Cells with Purified
SDF1 and Anti-SDF1 Antibody
Dissociated Wnt1 tumor cells were plated on 24 well collagen I-
coated plates (BD Bioscience) in 200 mL of mouse mammary
epithelial cell cultured media containing purified SDF1 (R&D
Systems), anti-GD, or anti-SDF1 antibody. Total cell viability was
determined by using CellTiter-Glo Luminescent Cell Viability
Assay (Promega). Luminescent signal was measured by Perkin
Elmer Envision 2102 multi-label plate reader.
Antibody Treatment of MMTV Tumor-Bearing Mice
Dissociated tumor cells (0.5610
6) were resuspended in
HBSS:matrigel (1:1) and injected into the #3 mammary fat
pads of 8–12 week-old NCR-nude mice. Mice with similar size
of tumors (100–200 mm
3)w e r es e l e c t e df o rt h ef o l l o w i n g
antibody treatments. Tumor-bearing mice were given intrave-
nous (i.v.) injections of hamster anti-SDF1 antibody (25 mg/kg;
raised against recombinant human SDF1; Genentech Inc.)
three times per week or with the same dose of hamster anti-
HSV Glycoprotein D (GD) control antibody. Anti-SDF1
antibody has been tested to inhibit both SDF1a and b forms
and it cross-reacts with mouse SDF1 (data not shown). Nude
mice were used for the antibody treatments to avoid immune
rejection of anti-SDF1 antibody because it was generated in
hamster. For anti-VEGF treatments, mice were given intra-
peritoneal (i.p.) injections of anti-VEGF antibody (5 mg/kg;
[25]) or injections of anti-Ragweed control antibody three times
per week. Anti-Gr1 (Ly-6G/C Ly-6G) antibody treatment was
done by i.p. injections of mice twice per week (10 mg/kg; BD
Bioscience).
Treatment of Wnt1 Tumor-Bearing Mice with Fzd8-CRD
Fzd8-CRD was purified as described in [24]. When Wnt1
tumors grown in EGFPtg/Rag2
2/2 mice reached ,500–
1000 mm
3, tumor-bearing mice were i.p. injected with Fzd8-
CRD (10 mg/kg). Tumors were collected at various time points
post injection, and total RNA was isolated.
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P values for tumor growth were calculated by Kaplan-Meier
Time to Progression method, and p values for two sample
comparisons were calculated by two-sided Wilcoxon Rank-Sum
test. JMP software was used for statistical calculations.
Supporting Information
Figure S1 Analysis of Wnt1 tumor vasculature and potential
factors that contribute to tumor vasculature. A, immunofluores-
cent stained Wnt1 and Her2 tumor sections with anti-MECA32
antibody (red) and DAPI (blue). The entire tumor section was
assembled from images taken by fluorescent microscope with a
10X objective, and inserts are zoom in depictions of that particular
sections. Total MECA32+ pixels were counted and divided by
total DAPI pixels to generate the percentage of MECA32+ pixels.
B, qRT-PCR analysis of SDF1a (light bars) and b (black bars)
mRNA transcripts in Wnt1 and Her2 tumors. All Taqman
reactions were performed in duplicate and normalized to
housekeeping RPL19 transcript level. Relative mRNA level for
each gene was calculated by the 2
2DDCt method by normalizing to
average transcript levels of first Her2 tumor (#1) sample.
Found at: doi:10.1371/journal.pone.0008611.s001 (8.76 MB TIF)
Figure S2 Determination of cells in Wnt1 tumors that produce
SDF1. A, qRT-PCR analysis of SDF1a, myoepithelial cell, and
luminal cell markers mRNA transcripts in various MMTV tumors.
Myoepithelial cell maker transcripts are shown as a combined
group: CK5 in stripped bars, P-cadherin in grey bars, and a-SMA
in black bars. Primary Wnt1 tumors are as indicated and all of the
other tumors are from passaged tumors. Relative mRNA level for
each gene was normalized to average transcript levels of normal
mammary glands. B, immunocytochemical analysis of the sorted
Wnt1 tumor cell populations stained with anti-CK5 (green), -
CK18 (red), and -vimentin (orange) antibodies, and DAPI stained
nuclei (blue). Immunofluorescent staining was done on sorted cells
by spotting sorted cells on glass slides, allowing cells to be dried
onto the slides, then fixing cells with 4% paraformaldehyde for 10
minutes at room temperature, and permeabilizing cells with cold
methanol for 10 minutes at 4oC. Fixed cells was blocked with
MOM (Vector Laboratories), incubated with primary antibodies,
followed by incubation with secondary antibodies. Finally, cells
were washed and mounted by Prolong Gold (Invitrogen)
containing DAPI dye. C, ELISA analysis of secreted SDF1a
protein in media taken from cultured myoepithelial cells
(Pcad
+EpCAM
lo), luminal cells (Pcad
2EpCAM
hi), and stromal
fibroblasts (GFP+CD45-) sorted from Wnt1 tumors. Error bars
represent standard deviations derived from triplicate plated cells.
Found at: doi:10.1371/journal.pone.0008611.s002 (10.21 MB
TIF)
Figure S3 Assessment of various BMDCs that may contribute to
tumor angiogenesis following anti-SDF1 treatment of Wnt1
tumors. FACS profiles and histogram/box plots of endothelial
progenitor cells CD34+VEGFR2+ cells (A), CD31+Sca1+ cells (B),
and tumor-associated macrophages (F4/80+; C) in the Wnt1
tumors following anti-SDF1 treatment of tumor-bearing mice.
Indicated number in the FACS profile represents percentage of
cells within the designated gate. P value was calculated by two-
sided Wilcoxon Rank-Sum test, and error bars represent standard
deviations from three independent FACs analysis. D, FACS
profiles and box plots of Gr1+CD11b+ cells in the peripheral
blood of Wnt1 tumor-bearing mice (n=10) following anti-SDF1
or control anti-GD treatment.
Found at: doi:10.1371/journal.pone.0008611.s003 (9.68 MB TIF)
Figure S4 Wnt1 tumor cells treated with purified SDF1 and
anti-SDF1 antibody. Dissociated Wnt1 tumor cells were cultured
in media containing control anti-GD antibody (30 mg/mL; blue),
SDF1 (100ng/mL; green) or various amounts of anti-SDF1
antibody (30 mg/mL in red or 100 mg/mL in orange). Cell
viability was measured everyday following treatments, and average
cell viability (RLUs) was calculated from three independently
plated cells. Error bars represent standard deviations.
Found at: doi:10.1371/journal.pone.0008611.s004 (7.36 MB TIF)
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